人类免疫缺陷病毒/丙型肝炎病毒混合感染者抗丙型肝炎病毒治疗的进展

田地; 徐小元

人类免疫缺陷病毒/丙型肝炎病毒混合感染者抗丙型肝炎病毒治疗的进展

田地,
徐小元

北京大学第一医院感染疾病科

基金项目:

国家自然科学基金(30771906)；高等学校博士学科点专项科研基金(20090001110081)；国家科技重大专项(2008ZX10002-013)；

详细信息

中图分类号: R512.91;R512.63
计量
- 文章访问数: 3572
- HTML全文浏览量: 29
- PDF下载量: 876
- 被引次数: 0
出版历程
- 出版日期: 2011-05-20

Treatment of hepatitis C virus infection in HIV/HCV co-infected patients

Research funding:

摘要

摘要: 由于人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)有相同的传播途径,HIV/HCV混合感染现象十分普遍,已成为严重的公共卫生问题。高效抗逆转录病毒治疗(HAART)的应用显著减少了与HIV感染相关的发病率和病死率,而HCV混合感染引起的慢性肝脏疾病日益成为HIV/HCV混合感染者发病和死亡的重要因素。HIV/HCV混合感染者HCV相关肝病的风险增加,有效的抗HCV治疗对延长这一人群的生存期至关重要。本文就抗HCV治疗对象的评估、治疗时机的选择、治疗的方法、治疗监测和疗效评估以及治疗注意的问题作一综述。
- HIV感染 /
- 肝炎,丙型 /
- 肝炎病毒属 /
- 重叠感染
Abstract: Duo to increasing prevalence and complex patient management, coinfection of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is a substantial medical and public health concern.The development of highly active antiretroviral therapy (HAART) results in a dramatic decrease in morbidity and mortality among HIV-infected patients, and liver disease caused by chronic infection with HCV has become an increasingly important cause of morbidity and mortality among HIV-infected patients parenterally with HCV.Since HIV/HCV coinfection is prevalent and increases the risk of HCV-associated liver disease, effective treatment for HCV is critical for the long-term survival of this group of patients.The assessment of coinfected patients, the time of treatment, the therapy of HCV infection, monitoring of coinfected patients before and during therapy of HCV infection, evaluation of the response to treatment, the caution during treatment are stated briefly.
- HIV infections /
- hepatitis C /
- hepacivirus /
- superinfection

HTML全文

参考文献(30)

[1]王慧, 贾继东.美国肝病学会2009年版丙型肝炎指南要点介绍[J].肝脏, 2009, 14 (3) :231-233.

[2]Soriano V, Puoti M, Sulkowski M, et al.Care of patients with hepatitis C and HIV-coinfection[J].AIDS, 2004, 18 (1) :1-12.

[3]Cote P, Baril JG, Hebert MN, et al.Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection:a practical guide for health care professionals[J].Can J Infect Dis Med Microbiol, 2007, 18 (5) :293-303.

[4]Moodie EE, Pant Pai N, Klein MB.Is antiretroviral therapy causing long-term liver damage?A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts[J].PLoS One, 2009, 4 (2) :e4517.

[5]中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 12 (4) :194-198.

[6]Valerio L, Yazdanpanah Y, Poizot-Martin I, et al.Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patientd[J].J Acquir Immune Defic Syndr, 2008, 47 (1) :50-55.

[7]Opravil M, Sasadeusz J, Cooper DA, et al.Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection[J].J Acquir Immune Defic Syndr, 2008, 47 (1) :36-49.

[8]Sanchez-Conde M, Berenguer J, Miralles P, et al.Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase[J].Clin Infect Dis, 2006, 43 (5) :640-644.

[9]Soriano V, Puoti M, Sulkowski M, et al.Care of patients coinfected with HIV and hepatitis C virus:2007 updated recommendations from the HCV-HIV International Panel[J].AIDS, 2007, 21 (9) :1073-1089.

[10]Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.Peginterferon Alfa-2a plus ribavirin for chronichepatitis C virus infection in HIV-infected patients[J].N Engl J Med, 2004, 351 (5) :438-450.

[11]Chung RT, Andersen J, Volberding P, et al.Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons[J].N Engl J Med, 2004, 351 (5) :451-459.

[12]Carrat F, Bani-Sadr F, Pol S, et al.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients:A randomized controlled trial[J].JAMA, 2004, 292 (23) :2839-2848.

[13]Laguno M, Murillas J, Blanco JL, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients[J].AIDS, 2004, 18 (13) :F27-36.

[14]赵四海, 刘恩岐, 成大欣, 等.HIV患者合并感染基因1和4型丙型肝炎病毒治疗效果的Meta分析[J].浙江大学学报 (医学版) , 2009, 38 (3) :315-319.

[15]Dore GJ, Torriani FJ, Rodriguez-Torres M, et al.Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection[J].AIDS, 2007, 21 (12) :1555-1559.

[16]De Bona A, Galli L, Gallotta G, et al.Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy[J].New Microbiol, 2007, 30 (3) :259-264.

[17]Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.APRICOT Study Group.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients[J].N Engl J Med, 2004, 351 (5) :438-450.

[18]Nicot F, Legrand-Abravanel F, Lafont T, et al.Serum J Clini Hepatol, May 2011, Vol.27, No.5concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV[J].J Med Virol, 2008, 80 (9) :1523-1529.

[19]Rendon AL, Nunez M, Romero M, et al.Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients[J].J Acquir Immune Defic Syndr, 2005, 39 (4) :401-405.

[20]Laguno M, Larrousse M, Murillas J, et al.Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin[J].J Acquir Immune Defic Syndr, 2007, 44 (2) :174-178.

[21]Lafeuillade A, Hittinger G, Chadapaud S.Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection[J].Lancet, 2001, 357 (9252) :280-281.

[22]Kakuda T, Brinkman K.Mitochondrial toxicity effects of ribavirin[J].Lancet, 2001, 357 (9270) :1802-1803.

[23]Bani-Sadr F, Carrat F, Rosenthal E, et al.Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment[J].Clin Infect Dis, 2005, 41 (12) :1806-1809.

[24]Reiberger T, Kosi L, Maresch J, et al.Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy[J].J Infect Dis, 2010, 202 (1) :156-160.

[25]Alvarez D, Dieterich DT, Brau N, et al.Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons[J].J Viral Hepat, 2006, 13 (10) :683-689.

[26]Vispo E, Barreiro P, Pineda JA, et al.Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir[J].Antivir Ther, 2008, 13 (3) :429-437.

[27]Bani-Sadr F, Denoeud L, Morand P, et al.Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination:does abacavir play a role?[J].J Acquir Immune Defic Syndr, 2007, 45 (1) :123-125.

[28]Amorosa VK, Slim J, Mounzer K, et al.The influence of abacavir and other antiretroviral agents on virologic response to HCV therapy among antiretroviral-treated HIV-infectrd patients[J].Antivir Ther, 2010, 15 (1) :91-99.

[29]Laufer N, Laguno M, Perez I, et al.Abacavir dose not influence the rate of sustained virological response in HIV-HCV co-infected patients treated with pegylated interferon and weight adjusted ribavirin[J].Antivir Ther, 2008, 13 (7) :953-957.

[30]Mira JA, López-Cortés LF, Barreiro P, et al.Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovie plus either lamivudine or emtricitabine as nucleoside analogue backbone[J].J Antimicrob Chemother, 2008, 62 (6) :1356-1373.

施引文献

资源附件(0)

访问统计